mln-8237 and lenvatinib

Immunohistochemical staining, sequencing, and genetic analysis of liver cancer tissues were performed. The antitumor efficacy of single-agent or combination treatment was measured by cell counting kit-8 assay and colony formation assays. Their antiproliferative and apoptosis activity is evaluated by cell cycle analyses and wound healing assays. The DNA-related proteins were also measured by Western blotting and immunohistochemical staining. The HepG2 xenograft model was used to detect the effects of lenvatinib-alisertib on the antitumor activity.. AURKA was found to be upregulated in HCC tissues (77.3%, 17/22). Combined alisertib and lenvatinib treatment significantly enhanced the inhibition of proliferation and migration in HepG2 and Hep3B cell lines compared to single-agent treatments (all. Our findings provide evidence for the possible use of alisertib in combination with lenvatinib in the treatment of HCC for better therapeutic outcomes.

Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Azepines; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; DNA Damage; Female; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Quinolines; Signal Transduction; Up-Regulation